By: Nicole Defeudis, Max Gelman
Endpoints Weekly reports on iECURE's gene therapy success for OTC deficiency, FDA CDER director Patrizia Cavazzoni's departure, and Verdiva Bio's $411M launch with Sciwind assets.
Max Gelman is a Senior Editor at Endpoints News. He specializes in medicine and healthcare, covering a range of topics including medical specialties, alternative medicine, healthcare technology, and the intersection of finance and healthtech. His work has also delved into cannabis and psychedelics, with insights on the FDA, markets, and biotech, and he has been featured in NewsBreak.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Max Gelman's articles predominantly cover the healthcare and pharmaceutical industry, with a focus on clinical trials, drug development, and medical research. His coverage heavily relies on cited data and press releases from private sector announcements.
Given Max's reliance on data-driven content, he is likely to be receptive to pitches that offer exclusive access to new findings or insights based on extensive data analysis within the healthcare and pharmaceutical sectors. Additionally, providing expert commentary or analysis of trends in biotech, pharmaceuticals, clinical trials or medical research might also capture his interest.
As Max does not have a specified geographic focus but seems to cover global developments in the industry; therefore sources with an international perspective may resonate well with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .